Introduction: Regorafenib is a third-line option in metastatic CRC, often overshadowed by its limited efficacy and high toxicity. Yet, rare cases of deep and even… […]
Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer
Background: LILRB4 and TSC22D3 in Inflammation HER2/neu mutations or amplifications can activate STAT3 to promote inflammation and suppressing adaptive immune responses. Elevated systemic inflammation-immune index… […]
